Associated Papers
Pharmacologic reversal of advanced Alzheimer's disease in mice and identification of potential therapeutic nodes in human brain.
Chaubey K et al.
Cell Reports. Medicine, 2026
Dual Regulatory Roles of USP10 in Tau Pathology and Neuronal Fate During Alzheimer's Disease Progression.
Takahashi M et al.
Molecular and Cellular Biology, 2026
A rare genetic variant confers resistance to neurodegeneration across multiple neurological disorders by augmenting selective autophagy.
Croce KR et al.
Neuron, 2025
Upregulating ANKHD1 in PS19 Mice Reduces Tau Phosphorylation and Mitigates Tau Toxicity-Induced Cognitive Deficits.
Tian X et al.
International Journal of Molecular Sciences, 2025
Neuronal glycogen breakdown mitigates tauopathy via pentose-phosphate-pathway-mediated oxidative stress reduction.
Bar S et al.
Nature Metabolism, 2025
PM2.5 triggers tau aggregation in a mouse model of tauopathy.
Liu C et al.
Jci Insight, 2024
The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges.
Zheng H et al.
International Journal of Molecular Sciences, 2024
Limitations of human tau-expressing mouse models and novel approaches of mouse modeling for tauopathy.
Sahara N et al.
Frontiers in Neuroscience, 2023
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.
Fernández-Calle R et al.
Molecular Neurodegeneration, 2022
Early lysosome defects precede neurodegeneration with amyloid-β and tau aggregation in NHE6-null rat brain.
Lee Y et al.
Brain : a Journal of Neurology, 2022
Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy.
Vermilyea SC et al.
Translational Neurodegeneration, 2022
P62 accumulates through neuroanatomical circuits in response to tauopathy propagation.
Blaudin de Thé FX et al.
Acta Neuropathologica Communications, 2021
Generation and Characterization of Novel Monoclonal Antibodies Targeting p62/sequestosome-1 Across Human Neurodegenerative Diseases.
Trejo-Lopez JA et al.
Journal of Neuropathology and Experimental Neurology, 2020
Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy.
Koller EJ et al.
Molecular Neurobiology, 2020
β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates.
Woo JA et al.
Proceedings of the National Academy of Sciences of the United States of America, 2020
Therapeutic Approaches to Alzheimer's Disease Through Modulation of NRF2.
Bahn G et al.
Neuromolecular Medicine, 2019
Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
Matsumoto G et al.
International Journal of Molecular Sciences, 2018
High-Molecular-Weight Paired Helical Filaments from Alzheimer Brain Induces Seeding of Wild-Type Mouse Tau into an Argyrophilic 4R Tau Pathology in Vivo.
Audouard E et al.
The American Journal of Pathology, 2016
Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate.
Bondulich MK et al.
Brain : a Journal of Neurology, 2016
Tau phosphorylation affects its axonal transport and degradation.
Rodríguez-Martín T et al.
Neurobiology of Aging, 2013
Stimulation of autophagy is neuroprotective in a mouse model of human tauopathy.
Schaeffer V et al.
Autophagy, 2012
Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy.
Schaeffer V et al.
Brain : a Journal of Neurology, 2012